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Abstract
The genes encoding the cytochrome P450 2C9 enzyme (CYP2C9) and vitamin K-epoxide
reductase complex unit 1 (VKORC1) are major determinants of anticoagulant response to warfarin.
Together with patient demographics and clinical information, they account for approximately one-
half of the warfarin dose variance in individuals of European descent. Recent prospective and
randomized controlled trial data support pharmacogenetic guidance with their use in warfarin dose
initiation and titration. Benefits from pharmacogenetics-guided warfarin dosing have been
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reported to extend beyond the period of initial dosing, with supportive data indicating benefits to
at least 3 months. The genetic effects of VKORC1 and CYP2C9 in African and Asian populations
are concordant with those in individuals of European ancestry; however, frequency distribution of
allelic variants can vary considerably between major populations. Future randomized controlled
trials in multiethnic settings using population-specific dosing algorithms will allow us to further
ascertain the generalizability and cost-effectiveness of pharmacogenetics-guided warfarin therapy.
Additional genome-wide association studies may help us to improve and refine dosing algorithms
and potentially identify novel biological pathways.
Keywords
Warfarin; pharmacogenetics; polymorphisms; personalized medicine
Warfarin remains one of the most effective anticoagulants indicated for the treatment and
prophylaxis of a range of prothrombotic cardiovascular, cerebrovascular, and hematologic
conditions.1-3 Although the cost-effectiveness and long-term safety of the latest generation
of oral anticoagulants (e.g., dabigatran, rivaroxaban, apixaban) have become a subject of
intense debate recently, warfarin continues to be the mainstay of anticoagulation after over
six decades in clinical use.4,5 Tens of millions of patients use warfarin worldwide, and there
are over two million warfarin users in the United States with over 30 million prescriptions
dispensed in 2004 alone.6,7 Due to the wide interindividual variability and narrow
therapeutic index of warfarin,8-10 there has been considerable interest in identifying genetic
and nongenetic variables that affect warfarin dose requirements.11-14
Initially developed to accelerate the rate with which therapeutic levels of anticoagulation
were achieved, fixed-dose algorithms have successively been superseded by more
sophisticated clinical algorithms based on patient demographics and other clinical
variables15; however, the success in ameliorating variability has been modest. Recently,
pharmacogenetic testing of candidate genes important in warfarin pharmacodynamics (e.g.,
vitamin K-epoxide reductase complex unit 1 [VKORC1]) and pharmacokinetics (e.g., the
cytochrome P450 2C9 enzyme [CYP2C9]) have yielded encouraging results in dose
initiation and titration,16-18 with potential for cost savings and reduction of length of
hospitalization.19 Several pharmacogenetics-guided dosing algorithms incorporate clinical
variables and patient demographics and have compared favorably with clinical data-only
algorithms.17,19-22 These studies have collectively contributed to the construction of a
prototypical framework for translating genetics and physiologic phenotypes into clinical
practice, to our improved understanding of human diversity, and to the advancement of
genetics-guided personalized medicine.
Developed from decades of international collaboration, international normalized ratio (INR)
as a standardized measurement of prothrombin time has served as the cornerstone for
warfarin-related genetic studies and enabled comparisons between laboratories and different
types of studies. Understanding how INR is derived is crucial because it represents the
phenotype with which genes and variants are correlated. Concerted international efforts have
recently revealed the differential contribution of genetic variants and transracial difference
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in warfarin dose requirements across ethnic groups and populations.12,23,24 For instance,
although VKORC1 and CYP2C9 together with clinical variables and patient demographic
information have been estimated to explain 40 to 50% of warfarin variability in individuals
of European descent, their effects are often markedly less in warfarin users of Asian,
African, Latin American, and other ancestry.14,21,23,25,26 These ethnic differences are of
clinical importance with scientific and public health implications, given the increasing
admixture and migration of populations worldwide with globalization.27,28
In this review, we discuss the definition of INR as a phenotypic correlate; the published
evidence for the major genetic determinants, VKORC1 and CYP2C9, in influencing warfarin
dose requirements in Europeans, Africans, Asians, and other ethnic groups; the clinical
science and utility of VKORC1 and CYP2C9; and other genetic variants that affect the
pharmacology of warfarin based on evidence from candidate gene and genome-wide
association studies (GWAS).
International Normalized Ratio
Studies designed to investigate genetic determinants of warfarin dose requirements,
pharmacogenetics-guided dosing of warfarin, and genome-wide quantitative trait mapping
of dose variations have taken advantage of INR as a standardized measurement of the
anticoagulant response to warfarin. INR is the ratio of the prothrombin time of a patient
(test) sample to a normal reference value (the mean of normal values, or Mean Normal PT,
MNPT) raised to the power of the international sensitivity index (ISI): (PTtest/PTreference)ISI.
Prothrombin time is assayed by applying tissue factor-containing thromboplastin to plasma
with the addition of excessive calcium to reverse the chelating effects of citrate in the
sample; the time for a sample to clot is the prothrombin time. The ISI value is supplied by
the manufacturer of an analytical system, and adjusts for reagent batch variability against a
standardized panel of control reagents endorsed by the World Health Organization.29
Periodic calibration of analytical instruments and the use of standardized assaying reagents
are essential for reliable INR testing. Since its introduction in the 1970s, the normalization
process has undergone several revisions.23,30
INR measures the extent of anticoagulation induced by warfarin. As a vitamin K antagonist,
warfarin inhibits the production of functional forms of specific vitamin K-dependent clotting
factors, including factors VII, IX, X, and II/prothrombin. Factor VII in the coagulation
cascade is also the chief clotting factor activated by tissue factor in thromboplastin that
triggers subsequent activation of factor IX, factor X, and prothrombin. Although INR is in
general relatively robust, it represents an artificial surrogate measurement of warfarin
anticoagulation reversible by exogenous tissue factor in vitro.
Warfarin Dosing in the Absence of Genetic Information
Following the development of standardized monitoring of anticoagulation with warfarin, it
became apparent that fixed-dose loading regimens (e.g., 10 mg on each of the first three
consecutive days followed by subsequent dose titration) were unreliable, often resulting in
over-anticoagulation in up to 35% of patients and prolonged hospitalization in those under-
anticoagulated. 31 Continual efforts led to the further refinement of algorithms and tailored
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dosing schedules with later incorporation of patient demographics (e.g., age, weight) and
clinical data (e.g., albumin levels) adaptable for use in inpatient or outpatient settings.15,31-35
Adjusted-dose warfarin therapy was found to be superior to fixed-dose warfarin (plus
aspirin) therapy, particularly evident in prospective, randomized clinical trials for the
prevention of stroke in patients with atrial fibrillation.1,36 Despite these advances, a
considerable degree of uncharacterized variability still existed, and studies aimed at
delineating these variables ensued.13,37
Of variables that affect warfarin dose variance, age accounts for 7% and its effects have
been found consistent in different studies and validated across ethnic groups.13,38-41 Flexible
dosing protocols have been developed that adjust for age.34 Nongenetic, complex
environmental variables including drug and food interactions, serum vitamin K levels, and
clinical factors (e.g., renal and hepatic function, presence of malignancy), among others,
have been correlated in some studies.37,42,43 Depending on the study population, clinical
factors may explain up to 20% of warfarin dose requirements.44 However, the common,
large interindividual dose requirements (e.g., in one study ranging from 7 to 280 mg per
week45) is not explained cumulatively by the majority of these uncommon though plausible
factors with modest effect size. For instance, amiodarone can reduce warfarin dose
requirement by approximately 18%38 but is used by < 10% of warfarin users, and in a
principal component analysis of 245 patients, of whom 21 took amiodarone, it was not
found to be a statistically significant determinant.13 Of 94 predictor variables analyzed in
one study, age and pharmacogenetic variables were found to be the strongest determinants
of warfarin dose requirements.13
Molecular Genetics, Polymorphisms, and Functions of CYP2C9 and
VKORC1
CYP2C9
Warfarin is a coumarin derivative that exists as a racemic mixture of S- and R-enantiomers.
The former has about three times the potency of the latter, and the cytochrome P450
enzyme, CYP2C9, is responsible for metabolism of the S-enantiomer. 6,46,47 CYP2C9 is
considered one of the most important P450 enzymes in the liver responsible for
metabolizing xenobiotics and a host of clinically important drugs, including anti-
inflammatory agents, oral hypoglycemic, oral anticoagulants, and diuretics.48
CYP2C9 is located on chromosome 10q24 spanning approximately 55 kb and contains nine
exons.49 Following reports that multiple cDNA sequences of CYP2C9 were cloned to
suggest a high level of polymorphism in the gene,49 the search for allelic variants was
spurred on. The convention of the nomenclature for CYP2C9 is such that *(number) denotes
the variant allele with reference to CYP2C9*1, the wild-type or major allele with the amino
acid sequences (Arg144/Tyr356/Ile359/Gly417) first identified in Northern Europeans.6,12
In this population, the allele frequency of CYP2C9*2 (R144C; rs1799853) and CYP2C9*3
was 12.5 and 8.5%, respectively.50 Functional significance of the allelic variants CYP2C9*2
in exon 3 and CYP2C9*3 (I359L; rs1057910) in exon 7 was demonstrated in expression
assays in vitro, providing evidence that both reduced-function variants resulted in impaired
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metabolism of S-warfarin.51,52 Respectively, enzymatic activity was reduced by
approximately 30 and 80%,17 and warfarin dose requirement was reduced by 14 to 20% and
21 to 49%.12,53,54 Modeling data from 137 patients suggested that through effects on rates
of drug clearance CYP2C9*2 and CYP2C9*3 predicted 58% of warfarin dose variation
based on the measured plasma S-warfarin concentration after initiation of warfarin
therapy.55 Although both variants were also found to correlate with an increased risk of
bleeding complications,17,53,56-60 neither stability of INR nor likelihood of severe over-
anticoagulation was associated.54
CYP2C9*4 was first reported in the Japanese population and associated also with reduced
warfarin dose requirements.61 Studies on individuals of African descent revealed a host of
other CYP2C9 variants not (commonly) found in individuals of European descent, including
CYP2C9*5 (rs28371686), CYP2C9*6 (rs9332131), CYP2C9*8 (rs7900194), and
CYP2C9*11 (rs28371685), among others, that impact on warfarin dose
requirements.25,62-64CYP2C9*14 through CYP2C9*19 were discovered in a cohort of
Southeast Asians from Singapore.65 There are at least 35 alleles of CYP2C9 documented6;
however, the effects of the majority of these alleles on warfarin metabolism and dose
requirements are yet to be characterized at present.
VKORC1
Vitamin K is an essential lipid-soluble micronutrient required for maintaining the
equilibrium of hemostasis and is available to humans from the gut microflora and dietary
intake of certain plants.66 As such, dietary variation, metabolic factors, and exposure to
certain antibiotics and environmental factors can impact on warfarin anticoagulation.67
Factors VII, IX, X, and prothrombin are vitamin K–dependent clotting factors that play
central roles in the coagulation cascade as discussed earlier. Proper functioning of these
factors requires posttranslational modification of glutamate side chains to γ-
carboxyglutamate catalyzed by γ-glutamyl carboxylase (gene encoded by GGCX).66
Reduced coagulant activity results when these proteins are partially γ-carboxylated or
decarboxylated. 68,69 The process of γ-carboxylation is dependent on vitamin K, a cofactor
that interchanges from the reduced (active) to the epoxide (inactive) state while glutamate is
converted to γ-carboxyglutamate. Recycling of the epoxide (vitamin K-2,3–epoxide) to the
reduced (vitamin K hydroquinone) form is catalyzed by vitamin K–epoxide reductase
(VKOR) and inhibitable by warfarin (or other coumarin derivatives such as
phenprocoumon).70 The VKOR complex unit 1 (VKORC1) is an 18-kDa protein located in
the endoplasmic reticulum70 and is expressed abundantly in hepatocytes.71
Through positional cloning72 and a siRNA gene knockdown approach,73VKORC1 was
localized to chromosome 16p11.2. VKORC1 consists of 5,125 base pairs and comprises
three exons.70 Loss-of-function mutations in VKORC1 can result in bleeding tendency,
whereas warfarin resistance can also stem from mutations in VKORC1.66,70,72,74 In
exploring the functional significance of polymorphisms, studies have found expression of
VKORC1 mRNA in several cell types and tissues, ranging from liver, myocardium, B
lymphocytes to lung cancer cell lines.21,70,71,73 Imbalance in allelic expression of VKORC1
(allelic mRNA:DNA) attributable to a regulatory polymorphism (3730A > G, rs9284) at the
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3′-UTR of VKORC1 was demonstrated in human liver specimens.71 Moreover, both the
common, noncoding VKORC1 single nucleotide polymorphisms (SNPs), – 1639G > A and
1173C > T, exhibited dose-dependent allele-specific effects on VKORC1 mRNA levels,71
and VKORC1 genotype is predictive of plasma S-warfarin concentration required to yield
therapeutic INR55 as well as the maintenance dose before initiation of therapy.75 These
findings extended the graded gene/haplotype-dose effect observed in the DNA transcript
analysis of haplotype groups A (associated with low dose of warfarin) and B (associated
with high dose of warfarin) incorporating the earlier SNPs that Rieder et al constructed in
their study.21 The – 1639G > A and 1173C > T polymorphisms are often tested
interchangeably in pharmacogenetic studies due to their complete linkage disequilibrium
(LD) with one another.6,76 Several SNPs associated with warfarin resistance including the
amino acid–changing (nonsynonymous) 106G > T (Arg36Tyr) variant77 and others have
been reported.74,78,79
CYP2C9 and VKORC1 in Dose Initiation and Titration
The pharmacogenetic utility of CYP2C9 and VKORC1 during warfarin therapy has been
examined in different clinical settings and populations over the last decade. Studies have
established that CYP2C9 and VKORC1 genotypes conjointly influence warfarin dose
requirements with impact on clinically significant endpoints and adverse events such as
bleeding complications.17,21,22,56,58,59,76,80-85 Several metrics have been used to measure
the strength, accuracy, and safety of pharmacogenetic guidance including time to therapeutic
INR, time to stable INR, percentage of time in the therapeutic range (%TTR), and
percentage of out-of-range (%OOR) INR in comparison with fixed-dose (empirical)
regimens.16-18 However, a uniform standard of comparison between studies is lacking.
In a review published in 2009, Moyer et al summarizes well the literature on CYP2C9 and
VKORC1 alleles and haplotypes, their prevalence across the three major races (individuals
of European, Asian, and African descent), the mean dose requirements stratified by race and
allele/haplotype, and the combined effects of CYP2C9 and VKORC1 on mean dose
requirements as a guidance for dose prescription.46 Since that time, tens of studies on
subjects of different ancestry correlating with CYP2C9 and VKORC1 alleles have been
published. The next section of this review article extends that summary and continues the
discussion on multiethnic differences in allele distribution and warfarin dose requirements
(see below).
To date, over a dozen pharmacogenetics-guided warfarin dosing algorithms incorporating
clinical and demographic information have been published, and a host of others specify
various modifications depending on the study objectives and populations examined.42,86,87
Notable examples include the International Warfarin Pharmacogenetics Consortium
(IWPC),20 Warfarin Genetic study in Sweden (WARG),26 CoumaGen,16 http://
www.warfarindosing.org,42 Warfarin Regimen using A Pharmacogenetics-guided Initiation
Dosing (WRAPID),18 and Newcastle22 algorithms. A pharmacogenetics-guided dosing
algorithm consists of a regression equation for calculating the warfarin initiation dose, an
institutional protocol for INR-guided dose adjustment during the maintenance phase, and a
timeline for specifying the dose initiation, maintenance, and follow-up intervals. The
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regression equation typically includes the following component variables: (1) patient
demographics (e.g., age, height, weight), (2) clinical information (e.g., interacting
medications, comorbidities), and (3) genetic information. These variable are factored into
the calculation of the warfarin dose.87
The majority of warfarin dose prediction, algorithm development, modeling, and
comparison studies are retrospective.6,46,86,88-96 Putting algorithms and dose prediction
modeling into practice, prospective studies are still scarce, but the numbers are
increasing.16-18,26,97-102 In the recently published prospective WRAPID study, 167 patients
were initiated on warfarin for atrial fibrillation or venous thromboembolism using a newly
developed pharmacogenetics algorithm incorporating patient demographics and clinical and
genetic information (VKORC1, CYP2C9*2 and *3) for initial dose loading and maintenance
dosing.18 Although the study lacked a control group, it demonstrated the clinical utility and
safety of pharmacogenetics guidance in determining loading and maintenance doses by the
lack of genotype-specific differences in time to first therapeutic INR and risk of over-
anticoagulation (INR > 4) even after adjusting for covariates.
The first prospective, randomized, controlled trial (CoumaGen) by Anderson et al compared
standard empirical dosing versus pharmacogenetic guidance in 206 patients and concluded
that pharmacogenetic-guided warfarin dose initiation more accurately and efficiently
approximated stable doses.16 A statistical significance in the primary end point of %OOR
INR was not observed between the two arms (possibly due to insufficient power), but
significance observed in exploratory analyses comparing wild-type and multiple variant
carriers prompted the launch of the CoumaGen-II study.17 The CoumaGen-II study
comprised comparisons of primary end points at 30 days and up to 3months of %OOR INRs
and %TTR between two groups in two arms. The first arm (n= 504 patients) compared a
modified IWPC pharmacogenetics algorithm (PG-1) against one in which use of CYP2C9
genotype information was deferred until after day 2 (based on the premise of the
pharmacokinetics of warfarin) plus the use of a dose-revision algorithm (PG-2) with the goal
of maximizing approximation of the initiation dose to the stable maintenance dose. The
second arm (n= 2,343 patients) compared PG-1/PG-2 against the standard parallel controls
consisting of patients being initiated on an empirical dose of warfarin (usually, 5 mg/d).
Following initiation (from day 8 onwards), the institutional chronic anticoagulation clinic’s
warfarin maintenance dosing protocol was applied to both arms. The sufficiently powered
study found no statistical difference in end points between PG-1 and PG-2 groups to suggest
superiority of either algorithm, and thus, both were combined as a PG cohort in the second
arm comparison against the standard dosing controls. The latter comparison saw highly
significant differences in the prespecified primary end points (%OOR INRs and %TTR), as
well as some secondary end points including average percent INRs ≥ 4 or ≤ 1.5, and average
percent INRs ≤ 1.5.17 As a metric of anticoagulation clinic quality (US national average of
%TTR is approximately 50 to 60%), patient’s compliance, longitudinal dosing stability, and,
more importantly, a measure of therapeutic benefits (e.g., protection from stroke in patients
with atrial fibrillation) derived from warfarin anticoagulation,103 the %TTR conferring a >
10% (TTR from 58.4 to 68.9% at 30 days, and from 58.6 to 71.2%) improvement with
pharmacogenetic guidance is remarkable. Clinical effectiveness of pharmacogenetic
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guidance in dose initiation and titration has also previously been demonstrated in the
prospective, nonrandomized Medco-Mayo study.19 Intriguingly, there is a growing
consensus that the lasting benefits of pharmacogenetic guidance extend beyond 1 week of
warfarin therapy.17,104 Other relatively small (sample size of around or fewer than 200
patients) prospective studies with or without randomization have reported mixed or negative
results, possibly related to the study design, power, differences in patient populations, or
other factors.105,106 Several large, randomized clinical trials (e.g., COAG, GIFT, EU-PACT)
approaching or exceeding 1,000 patients are ongoing107 that should help to address
questions not answered by available studies.
Interethnic Variability and Distribution of CYP2C9, VKORC1 and Other
Variants
Race and ethnicity are recognized determinants of warfarin dose requirements.108-110
African ancestry generally confers the highest adjusted mean weekly warfarin dose (43 mg,
range: 39 to 47 mg) compared with their European (36 mg, 34 to 39 mg), Latin American
(31 mg, 25 to 37 mg), and Asian (24 mg, 21 to 27 mg) counterparts.38 The African
population is also the most genetically diverse and heterogeneous.111
Dose variability attributable to genetics is less well captured in non-Europeans, especially
Asians and Africans.24 Featuring VKORC1, CYP2C9*2 and CYP2C9*3 variants, and
clinical information, the IWPC algorithm that was developed from an international panel of
approximately 5,000 patients consistently performed well in individuals of European descent
demonstrating approximately 50 to 65% or higher of dose variability with accuracy in the
range of 10 to 20% of maintenance dose.20,24,112 However, only about 30 to 40% (range: 8
to 46%) dose variance is explained in non-European populations depending on the
study,92,112-114 and suggests the inadequacy of VKORC1, CYP2C9*2, and CYP2C9*3, or
missing pharmacogenetic information for non-Europeans.
Warfarin Users of African Descent
An analysis of VKORC1 distribution has shown a haplotype A21 frequency of 10.6% in
African American (n= 273) and 35% in European-Americans (n= 302).115 In general,
VKORC1 and CYP2C9 variants account for upward of 30 to 40% of dose variance, even
with incorporation of clinical information in individuals of African descent,112,114-116 and
depending on the number of CYP2C9 variants included in the analysis.25 In an analysis
using the IWPC dosing algorithm that derived a 29% dose variance in a study population of
African Americans,112 addition of the CYP2C9 variants CYP2C9*6 (rs90449157),
CYP2C9*8 (rs90442184), and CYP2C9*11 (rs90481096) (all rare in Europeans) improved
the variance explained to 41%.112 In a study of warfarin clinic subjects with discrepant
therapeutic and algorithm-predicted doses, Scott et al demonstrated in one African American
patient on a lower-than-expected dose (14.4 mg/wk) the failure of 15 published algorithms
to accurately predict the required dose (a mean recommended dose of 41.8 mg/wk, range:
24.9 to 52.2 mg/wk).25 The study pointed out the potential utility of CYP2C9*8 (rs7900194;
allele frequency of 0.047) in African American and recommended its inclusion in
conjunction with CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, and CYP2C9*11
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(combined allele frequency of 0.133) for improved dose predictability.25 Further support in
using CYP2C9*8 for warfarin dose prediction in Africans has come from a study on 213
South African blacks,117 and another on 226 African American that illustrated improvement
of the percent dose variance explained to approximately 30 to 36% with clinical variables
and VKORC1– 1639G >A.62
Heterogeneity of the African race is evident in a study on 993 Africans that examined 14
SNPs in seven genes previously reported to influence warfarin dosage.118 Comparing the
different native African populations with migrant individuals of Asian and European
ancestry in South Africa, CYP2C9*2 was found to be monomorphic and VKORC1 SNPs had
low variant allele frequencies (0.03 to 0.04) in the Africans, indicating limited utility of
those variants in South African blacks. Nonetheless, differences in allele frequencies of the
panel of SNPs tested have enabled the differentiation of ancestral lineage among the African
subpopulations, including native South Africans, Massai Kenyans, Luhya Kenyans, and
Yoruba Nigerians; close affinity was unexpectedly observed between the latter two
populations.118 In a study of individuals with warfarin resistance, the VKORC1 Asp36Tyr
variant initially identified in Jewish individuals of Ethiopian (allele frequency of 15%) and
Ashkenazi (4%) origins was reportedly common in 154 Ethiopian blacks (also with an allele
frequency of 15%).119 The great level of genetic heterogeneity, extensive population
substructure, and less LD in the African population compared with other races111 explains
the difficulties in analyzing individuals of African descent, and demands close attention to
their characterization.
Warfarin Users of Asian Descent
East Asians typically require on average about 3.0 to 4.0 mg/d, or about 21 to 28 mg/wk, of
warfarin to achieve therapeutic INR.38,120-122 A VKORC1 haplotype analysis comparing
five East Asian populations (Han Chinese from Taiwan and China, individuals from
Indonesia, the Philippines, Thailand, and Vietnam) with a South Asian population (Indians
residing in Taiwan) totaling 553 patients reported relatively close similarities in variant
frequencies among East Asians, but significant differences were observed when compared
with Indians.123 Allele frequencies of the wild-type CYP2C9*1 and the VKORC1 1173C > T
variant found commonly in East Asians (allele frequencies of > 0.90 and 0.8 to 0.9,
respectively) are similar among the Chinese,23 Japanese,120 and Koreans.124 At the
subpopulation level, the Bai, Tibetan, and Han Chinese ethnic groups also displayed similar
VKORC1 3673G > A allele frequencies of 92.8, 90.2, and 90.8%, respectively, for the A
allele.125 An allele-specific, graded dose effect in accordance with the CYP2C9 and
VKORC1 genotypes is seen in Asians as for the well-studied European populations.23,126
Whereas the African populations have in general a repertoire of reduced-function CYP2C9
variants (e.g., CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*11) that influence warfarin
dose response,25,112,117 the relatively less heterogeneous East Asian populations have allele
frequencies of > 90 to 95% at the wild-type CYP2C*1, and frequencies of 80 to 90% at the
reduced-function VKORC1 variants (e.g., 1173TT, – 1639AA) that could explain their
overall lower warfarin dose requirements compared with their African and European
counterparts. 110,124 By far the single factor that explains the greatest proportion of dose
variation is VKORC1, estimated at 20 to 30% from genotyping studies and GWAS,14 and is,
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hence, a main source for the reduced dose requirement in East Asians. Collectively, patient,
clinical, and genetic information account for 40 to 50% (mean: 48%, range: 33.2 to 76.8%,
from 17 East Asian studies of dose variation explained.86,102,120,124,126-137
Multiethnic studies on Southeast Asians have shown greater similarity between Malaysians,
Indonesians, Thais, and Chinese than with Indians.27,123,138-140 For instance, CYP2C9*2 is
consistently absent in these Southeast Asian populations but present in up to 5.9% of
Indians.141,142 The dose variance explained by CYP2C9 and VKORC1 along with patient
demographics and clinical data varied considerably from 15.4% in an Indonesian study,143
36.5% in a Malaysian study,144 to 61% including CYP4F2 in a multiethnic Singaporean
study.27
Warfarin Users in Latin America, Other Regions, and Heterogeneous Populations
Apart from indigenous individuals native to Central and South America (Native Americans)
in whom a unique frequency distribution of VKORC1 SNPs is observed,145 immigrant
populations such as Brazilians and Argentinians of European descent have allele frequencies
and profiles that follow their native European counterparts.146,147 The direction of gene
effects from allelic variants is congruent between the major populations and Hispanic
Americans, Colombians, and Puerto Ricans.148-151 These effects were also found consistent
in the Turkish,152,153 Lebanese,154,155 Omani,156 Iranian,156 Egyptian,157,158 and
Jewish97,159 populations. Several of these populations exhibit allele frequencies intermediate
between the major races (Africans, Asians, and Europeans), and appear in line with the
human migration patterns and the bottleneck of the founding of non-African populations
some 50,000 to 100,000 years ago as evidenced by lower genetic diversity, a considerably
higher level of LD, and more similar patterns of LD.111
Genomic Basis for CYP2C9 and VKORC1 as Determinants of Dose Variance
and the Remaining Genetic Determinants
Over the past 5 years, advances in high-throughput technologies have made feasible the
agnostic interrogation of SNPs genome-wide. Currently, two GWAS on warfarin dosage
have been published with individuals of European ancestry.11,14 Cooper et al11 genotyped
approximately 500K SNPs in 181 subjects as a discovery phase and then replicated the best
signals with a p value of less than 10−4 in another 374 samples (Table 1). In the discovery
phase, only SNPs in VKORC1 reached the study’s level of genome-wide significance (p<
10−7), whereas polymorphisms in CYP2C9 were genome-wide significant post-replication.
The next best signal was rs2286461 near FGFBP2 on chromosome 4, which had a p value of
6.6 × 10−7 in the discovery set. However, the joint discovery and replication analysis yielded
a p value of 1.8 × 10−5, suggesting that the effect in the discovery and replication sets were
in opposite directions. The same was apparent for almost all the other regions that were
selected for replication. One exception was rs216013 in the intron of CACNA1C on
chromosome 12, which reached a p value of 8.6 × 10−7 in the joint analysis, with a p value
of 9.2 × 10−5 in the discovery set. VKORC1 and CYP2C9 explained 25 and 9% of the
warfarin dose variance, respectively, whereas inclusion of nongenetic information (age,
gender, treatment with amiodarone, treatment with losartan, and weight) increased the
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variance explained to 47%. This study11was underpowered to identify variants with small
contribution to warfarin dose variance; for example, it had 80% power to detect a SNP
association explaining 20% of the variance in warfarin dosing, which is almost the effect of
VKORC1.
VKORC1 and CYP2C9 were also statistically significant in another GWAS of Swedish
individuals.14 Takeuchi et al14 applied a two-stage approach with 1,053 subjects in the
discovery set and 588 in the replication set (Table 1). The study had 80% power to identify a
genetic variant explaining at least 1.5% of the warfarin dose variance. The minor alleles of
both VKORC1 and CYP2C9 reported SNPs had protective effects on warfarin dose (i.e.,
carriers of the minor alleles required less warfarin), and the variance explained was 28.3%
and 7.5%, respectively. In the primary analysis, no other region reached the a priori defined
level of genome-wide significance of 10−7. In a secondary analysis, the authors fitted a
multivariate regression adjusting for the effects of VKORC1, CYP2C9, age, and sex,
identifying rs2108622 in exon 2 of CYP4F2 on chromosome 19 at genome-wide level. The
carriers of the minor allele had an increase of warfarin dose and thus an opposite effect of
VKORC1 and CYP2C9 and explained around 1.5% of overall variance in the discovery set.
The authors also investigated 2,530 copy number variants (CNVs); however, none of these
were found to be associated with the warfarin dose.14 Corroborating those findings, a
focused genotyping study of CNVs in CYP2C9, VKORC1, CYP4F2, GGCX, and CALU
from 178 multiethnic patient samples (Americans of European, African, Latino, and Asian
descent), in addition to 350 additional samples testing for CYP2C9 exon 8, found that all
participants had two copies of the gene.45
Findings from GWAS on warfarin dose in Japanese individuals bore remarkable
resemblance to those of their (European) counterparts.160 Cha et al split their discovery set
into subjects with high and low warfarin dose and treated the phenotype as binary.
VKORC1, CYP2C9, and CYP4F2 affected warfarin dose in the same direction as in the
European samples (Table 1). The effects of these 3 loci reportedly explained approximately
43% of the phenotypic variance in a replication set.
Interestingly, a GWAS of acenocoumarol maintenance dose in Europeans identified culprits
in the same three regions. The strongest signal was in rs10871454 in STX4A gene, which is
in complete linkage disequilibrium (r2= 1 and D′= 1) with rs9923231 in VKORC1 (Table 1).
All three effects had the same direction as per the warfarin GWAS and could explain similar
portions of the variance of acenocoumarol maintenance dose, highlighting the importance of
these loci in anticoagulation therapy using a dicoumarol/coumarin derivative. Furthermore,
this study found rs1998591 in CYP2C18 to have a genome-wide effect (p< 5 × 10−8), while
accounting for ~ 1% of the acenocoumarol dose variance. Although published GWAS on
warfarin dosage report no information on CYP2C18, polymorphisms in the same gene have
been suggested to alter warfarin-related phenotypes in candidate gene studies.130,161
GWAS of warfarin dose have been relatively successful so far. Besides the strong effects in
VKORC1 and CYP2C9, there is evidence that more genes could play a role, although with
small effects. CYP4F2 is a notable example; because of its small contribution to variance
explained (~ 1%), the underpowered GWAS by Cooper et al could not have identified it.
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Evidence from GWAS in other traits suggests that larger discovery sets and meta-analysis of
GWAS can increase power and help identify variants with (very) small effects.162
Furthermore, none of the earlier GWAS has accounted for the effect of population
stratification (differences in allelic frequencies between subpopulations) or reported the
genomic inflation factor (λ).163 Typically, population stratification can cause spurious
associations; however, failure to account for population substructure can also cause loss of
power to detect true effects.164
Conclusions and Implications
VKORC1 and CYP2C9 in conjunction with patient demographics and clinical information
explain about half of the dose variance in patients taking warfarin, particularly in individuals
of European descent. Current evidence and existing pharmacogenetic and genomic data
indicate that another one-half of dose variance is yet to be accounted for by genetic and
nongenetic factors. Due to limitations of the previously performed GWAS, it remains
unclear whether additional common, large-effect size genes similar to VKORC1 and
CYP2C9 exist.
In the era of globalization, entry into health care systems is increasingly made by
multiethnic and admixed populations, as evident in the patient population served by clinics
and hospitals in major urban areas such as New York City,64 Toronto,28 Singapore,123 and
others. The development and advances in warfarin pharmacogenetic testing is already
serving as a prototypical framework for future developments to follow. The priority will
stand with how best to deliver health care and medicines safely and effectively to diverse,
multiethnic populations in an individualized manner, and pharmacogenetics will likely be a
major contributor.
Globalization and the Information Age have accelerated access to technology, and delivered
direct-to-consumer personalized genomic testing.165 Genetic/genomic data are already
integrated with electronic medical record (EMR) system featuring capacity for clinical
use.112 Using warfarin pharmacogenetic testing as an example, one could imagine the one-
off test results becoming available within 1 hour,17,166 ready for use at the time of warfarin
initiation based on a personalized dosing algorithm, and then the pharmacogenetic data
being stored in an EMR until future use when the latest variables (e.g., advancing age, new
current medications, comorbidities) are updated and the warfarin dose calculated and
dispensed automatically at no additional cost. In a cost-effectiveness analysis in 2009, it was
suggested that if warfarin pharmacogenetics guidance could reduce the OOR INR by 5 to
9%, then testing would be beneficial.167 In the latest prospective, randomized, controlled
trial, pharmacogenetic guidance was found to increase the OOR INR by 12%.17
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